TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02431156

Intervention type: OTHER
Intervention: Assessment of visual capacity
Description: Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC
Study: NCT03216538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.4 ml daily p.o.
Study: NCT02074488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balancing Act exercise curriculum
Description: Balance improvement exercise curriculum titled Balancing Act
Study: NCT04482699

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RAPA-501-Allo off-the-shelf Therapy of COVID-19
Description: Allogeneic off-the-shelf RAPA-501 cells
Study: NCT02074488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Brochure
Description: Informational Brochure on falls prevention

Intervention type: OTHER
Group type: OTHER
Intervention: Informational Brochure
Description: Informational Brochure on falls prevention
Study: NCT03875365

Intervention type: PROCEDURE
Intervention: POPE
Description: Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
Study: NCT04286750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Description: ACT-1004-1239 administered as hard capsules for oral use.
Study: NCT05732181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The skin lidocaine patch.
Description: The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patch without drugs
Study: NCT02860182

Intervention type: OTHER
Intervention: measure the elastic properties of aortic wall

Intervention type: OTHER
Intervention: measure the elastic properties of aortic wall
Study: NCT04286750

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered as hard capsules for oral use.
Study: NCT05276037

Intervention type: OTHER
Intervention: Liver transplantation
Description: Both groups will receive the same advantages on the LT waiting list (SE points)
Study: NCT03984045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Intranasal 2% lidocaine delivered directly to SPG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine Injection
Description: intravenous prochlorperazine at 0.15mg/kg max 10 mg
Study: NCT02680418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study: NCT01940419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1g Tranexamic acid iv administered over 10 minutes just before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml sodium chloride iv administered over 10 minutes just before surgery
Study: NCT02951260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 17 days treatment with metformin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 17 days treatment with placebo
Study: NCT03601299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional food
Description: Increasing traditional food consumption through Head start programs in Alaska
Study: NCT04482699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501-Allo off-the-shelf Therapy of COVID-19
Description: Allogeneic off-the-shelf RAPA-501 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501-Allo off-the-shelf Therapy of COVID-19
Description: Allogeneic off-the-shelf RAPA-501 cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RAPA-501-Allo cell placebo
Study: NCT04662242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium Supplement
Description: Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium Supplement
Description: Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 100ml iv infusion for 7 days
Study: NCT02803684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination with tensor diffusion protocol acquisition. No injection needed.
Description: standard MRI examination
Study: NCT03986957

Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study: NCT02525679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130 (spesolimab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02629861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
Study: NCT04662242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 100ml iv infusion for 7 days
Study: NCT04003077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser meridian massage
Description: The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
Study: NCT01566643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA5-RACM7
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA3-RACM7
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study: NCT02629861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Study: NCT03888560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
Study: NCT03366337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Description: Bardoxolone 5 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Description: Bardoxolone 5 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Description: Bardoxolone 5 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Description: Bardoxolone 5 mg capsules
Study: NCT01479478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic dietary supplement
Description: Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
Study: NCT01142271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth-I
Description: Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux en Y
Description: Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
Study: NCT01566643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA7-RACM7
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study: NCT01593163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen EchoG
Description: Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard ibuprofen treatment
Description: Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
Study: NCT03247205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HipERS
Description: This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
Study: NCT04203654

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive-behavior group therapy
Description: cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual supportive psychotherapy
Description: Individual supportive psychotherapy 3 sessions during the 16-week treatment period
Study: NCT04496700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole blood donation and transfusion
Description: The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole blood donation and transfusion
Description: The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole blood donation and transfusion
Description: The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only.
Study: NCT02704676

Intervention type: OTHER
Intervention: marker(CA-125)
Description: measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)

Intervention type: OTHER
Intervention: marker(CA-125)
Description: measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)

Intervention type: OTHER
Intervention: marker(CA-125)
Description: measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
Study: NCT04257955

Intervention type: BEHAVIORAL
Intervention: Interview and evaluation of Engagement
Description: (i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
Study: NCT04182698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy for An Luo
Description: Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.
Study: NCT01783717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
Study: NCT00703833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0777
Description: Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (unspecified)
Description: matching placebo
Study: NCT00465491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: picoplatin
Description: IV picoplatin 150mg/m2 q3wk

Intervention type: OTHER
Group type: OTHER
Intervention: best supportive care
Description: best supportive care
Study: NCT02150473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: adalimumab 40 mg every other week in combination with MTX for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo the same amount as adalimumab
Study: NCT03293498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu
Description: Vaccine
Study: NCT00077610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa or beta
Description: intravenously 3 times weekly for 52 weeks, as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO0503821 (1x/2 Weeks)
Description: 60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO0503821 (1x/4 Weeks)
Description: 120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
Study: NCT04089020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support for walking to school
Description: 5 modules that address psychosocial skills, with ongoing text messaging.
Study: NCT03494114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-EC2115
Description: Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-EC2115
Description: Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
Study: NCT04632706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to the Active IMP.
Study: NCT00729131

Intervention type: DRUG
Intervention: Etanercept inhibition of ozone-induced airway hyper-responsiveness.
Description: Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
Study: NCT04892316

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: The training dataset was used to train the model, which was validated and tested by the other two datasets.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: The training dataset was used to train the model, which was validated and tested by the other two datasets.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: The training dataset was used to train the model, which was validated and tested by the other two datasets.
Study: NCT00897949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (MK0462)
Description: Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (MK0462)
Description: Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo to rizatriptan
Study: NCT01553747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets twice daily
Study: NCT01197157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: • Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
Study: NCT01810094

Intervention type: DEVICE
Intervention: Fracture Fixation
Description: Thoracolumbar Fracture Fixation
Study: NCT03736759

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
Study: NCT01510652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiP Group
Description: Implantation of standard Left Ventricular (LV) lead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quad Group
Description: Implantation of quadripolar Left ventricular (LV) lead Quartet
Study: NCT03452124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I quit ordinary smoking (IQOS)
Description: I quit ordinary smoking (IQOS) assisted cessation program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette
Description: Conventional cigarette smoking continuation
Study: NCT01514994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioScore's Valvuloplasty Scoring Balloon
Description: All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
Study: NCT00273741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo capsules
Study: NCT04633655

Intervention type: OTHER
Intervention: outcome measures for CIPN testing
Description: questionnaires administration, physician based scales for CIPN data collection
Study: NCT00110344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
Study: NCT00897884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tablet, taken 3 times a day for 2-3 weeks
Study: NCT03625076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular Lidocaine
Description: 20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedural Sedation with etomidate or propofol
Description: Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.